BYD Launched BAO 5 under Its New Brand FANGCHENGBAO and the DMO Technology
BYD, the world’s leading manufacturer of new energy vehicles and power batteries, introduced FANGCHENGBAO, its new professional personalized sub-brand, as well as its sophisticated technology: the Dual Mode Off-road (DMO) Super Hybrid Platform. The first model of the new brand - BAO 5, a super hybrid off-road SUV harnessing the DMO technology was launched during the event as well as a concept car BAO 8 and BAO 3.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230817807422/en/
Wang Chuanfu, the Chairman and President of BYD (Photo: Business Wire)
Wang Chuanfu, the Chairman and President of BYD, said at the launch event that FANGCHENGBAO aspires to redefine vehicular experience by offering an unparalleled blend of professionalism and personalization to global users, driving a profound "revolution" in the NEV landscape, transforming cars into unique, tailor-made assets for every individual.
The Brand: A great leap in New Energy Vehicle Sector
The brand name FANGCHENGBAO, derived from Chinese phonetics, symbolizes a blend of precision ("FANGCHENG" for "formula") and agility ("BAO" for "leopard"), introducing a series of specialized technologies, including the DMO Super Hybrid Off-Road Platform, which is also inaugurated at the event.
FANGCHENGBAO envisions the confluence of state-of-the-art new energy technologies and diverse users' preferences will unlock unprecedented user experience: whether journeying through the vast wilderness, speeding on a racetrack, navigating through bustling cityscapes, or cruising on highways; whether seeking occasional exhilaration or traversing daily commutes, an exclusive driving experience for every scenario is now within reach.
To meet this end, FANGCHENGBAO will integrate BYD's apex technologies, forward-looking designing ethos, and the vertically integrated supply chain system, in order to enrich every vehicle with distinctive tailor-made possibilities.
FANGCHENGBAO symbolizes the fusion of new energy and boundless possibilities, turning every individual's dreams into tangible reality.
The DMO Technology: Unleashing the Might of Electricity for Individual Empowerment
At the event, BYD unveiled the innovative DMO Super Hybrid Off-Road Platform, signaling a significant pivot from traditional gasoline engines. This platform powers the FANGCHENGBAO vehicles, promising a transformative off-road experience while championing energy efficiency, and empowering every user with pinnacle technology.
The DMO combines BYD's Revolutionary Non-Load-Bearing Frame Designed for Hybrids with a specialized off-road hybrid architecture. This integration taps into BYD's expertise in high-performance chassis, intelligent electric four-wheel drive, and off-road powertrains. As a result, DMO strikes an unparalleled balance between vehicle safety, powerful off-roading, and energy consumption.
Instead of traditional modifications that add weight and increase rollover risks, the DMO innovatively fuses the Blade Battery and high-strength steel frame, evolving to the Cell to Chassis (CTC) technology. This not only ensures battery safety during extreme off-road scenarios but also significantly boosts overall vehicle safety.
The platform also boasts features like the longitudinal EHS electric hybrid system and an industry-first off-road rear-drive powertrain, as well as the Xiaoyun longitudinal high-performance engine, delivering a formidable system power of more than 500kW and an unmatched traction of 32,000N. Moreover, DMO vehicles utilize intelligent torque control technology to minimize the turning radius to just 3.4 meters. Also thanks to its powerful drive and precise electronic control, users can effortlessly navigate through swampy terrains, rugged mountains, gravelly slopes, and many other extreme terrains with the DMO. Equipped with three Differential Locks, drivers can switch to low-speed gear, which is designed for off-road scenario, with a push on the button.
Building on this innovative architecture, DMO incorporates a double-wishbone independent suspension at both ends, which, when paired with DiSus-P Hydraulic Body Control System, assures SUV-like comfort even in challenging terrains. The platform achieves 35% fuel savings compared to gasoline-powered off-road vehicles.
DMO stands out as a predominantly electric-driven, professional-grade off-road platform. It represents the culmination of over twenty years of BYD's cutting-edge technological evolution and insights from the experience gleaned from millions of BYD PHEVs. This platform transcends the conventional and substantially amplifies the capabilities of electric mobility. With its vast technical prowess, the DMO surmounts challenges that new energy vehicles typically encountered across scenarios, recalibrating the paradigm for off-road vehicular design and functionality.
Looking ahead, FANGCHENGBAO is set to venture into domains such as off-road SUVs and sports cars, where traditional gasoline vehicles predominate, starting from models with the DMO platform.
The New Models: Pioneers With Leading Technology and Unique Product Offerings
Three FANGCHENGBAO's models offer a powerful product lineup, catering to a range of individual preferences, demonstrating its robust product matrix and its dedication to professionalism and individuality.
The BAO 5, positioned as a super hybrid off-road SUV, is equipped with key technologies like DMO and DiSus-P Hydraulic body control system. Its design seamlessly combines industrial aesthetics with robust power, delivering unparalleled stability and safety for users.
As a brand emphasizing customization, FANGCHENGBAO offers the BAO 5 a variety of front-face structures that can be seamlessly integrated or adjusted. It provides a flexible foundation tailored to each user's unique modification preferences.
The BAO 8 concept car, named SUPER 8, unveils the brand's futuristic vision for off-road SUVs. Inspired by sci-fi battlefields, this design ensures robust integration and enhanced protection, inspiring driver confidence. Furthermore, preliminary details about the BAO 3 were revealed, hinting at a trendy model geared towards diverse audiences with a playful spirit.
To ensure consistent service and experience quality, FANGCHENGBAO will adopt a Direct-to-Consumer (DTC) model in the initial phase in the Chinese market, planning to reach 60 cities by 2024. It is also announced that the BAO 5 will have its first offline debut at the Chengdu Motor Show, starting August 25th.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817807422/en/
Contact information
Asia-Pacific: Liya Huang, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com
tel: +56 9 96443906
Brazil: Pablo Toledo, pablo.toledo@byd.com tel: +19 3514 2554
Middle East and Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom